Chandigarh: A case has been registered against a pharmaceutical company for trying to mislead PGI by creating a fake letter from CDSCO (Central Drugs Standard Control Organisation) Baddi to prove the quality of substandard medicine in sample testing. Earlier, after questions were raised on the company’s medicine, PGI had banned it for two years. When there was doubt on the investigation report, PGI management re-investigated the report with CDSCO Baddi and DCGI, CDSCO Delhi, and it came to light that the letter was fake. After this PGI handed over the case to Sector-11 police station. Police have registered a case against CMG M/s Biotech Private Limited under sections 420, 467, 468, 471 and 120B of IPC and started investigation.
According to the information, in the year 2018, on behalf of the Drug Inspector of PGI, a sample of Technolimus capsules was collected from the store of the pharmaceutical company of Chandigarh at PGI, which was declared sub-standard by RDTL (regional drugs testing laboratory), Chandigarh. After this the matter was placed before the Drug Committee, in which the company was banned for two years. After this, the report of CDL Kolkata was placed before the committee on behalf of the company officials, in which it was said that the medicine in question was as per the standards.
To verify the authenticity of the report, PGI wrote to CDSCO Baddi, but when no reply was received, DCGI wrote to CDSCO Delhi. After this, PGI received a letter through a normal post with the letterhead of Deputy Drug Controller BK Samantre, in which the report of CDL Kolkata was justified. When PGI again wrote to CDSCO suspecting that the letter was fake, Deputy Drug Controller BK Samantre said that neither this letter was issued by him nor was his signature on the letter. After this, PGI handed over the matter to the police, on which investigation has been started.
